Payment overview · 2025
General Payments
$2,057.47
95 reported records · 20 companies
Healthcare provider profile · identity verified
Paul Chike Okolocha, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GARY, IN · NPI 1629193321
Verified facts
What the public records show
CMS Open Payments records show Paul Chike Okolocha, M.D. received $2,057.47 in general payments during 2025 across 95 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Farxiga, Linzess, Mounjaro, Rexulti, Trelegy Ellipta, Veozah.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $378.72 | 18.4% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $277.80 | 13.5% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $250.04 | 12.2% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $161.55 | 7.8% | 15 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $144.22 | 7.0% | 7 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $133.22 | 6.5% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $102.06 | 5.0% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $98.74 | 4.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.42 | 4.0% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $78.14 | 3.8% | 4 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $73.17 | 3.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $54.52 | 2.6% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.06 | 2.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.41 | 2.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.55 | 1.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $28.19 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.73 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.00 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.28 | 0.7% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $13.65 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,057.47 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $378.72 | 17 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $250.04 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $246.28 | 12 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $161.55 | 15 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $133.22 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $129.53 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $127.13 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $98.74 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $78.14 | 4 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $73.17 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.68 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $54.52 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $54.06 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.89 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.41 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.41 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $33.53 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.89 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.55 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $28.19 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 76 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 53 | exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
76 | 36 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 21 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 842 | 152 |
| Alprazolam | Alprazolam | 581 | 101 |
| Gabapentin | Gabapentin | 535 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 483 | 185 |
| Ibuprofen | Ibuprofen | 419 | 121 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 320 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 312 | 97 |
| Meloxicam | Meloxicam | 272 | 130 |
| Furosemide | Furosemide | 269 | 92 |
| Omeprazole | Omeprazole | 250 | 81 |
| Prednisone | Prednisone | 250 | 138 |
| Trazodone Hcl | Trazodone Hcl | 209 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 194 | 35 |
| Potassium Chloride | Potassium Chloride | 189 | 56 |
| Losartan Potassium | Losartan Potassium | 188 | 67 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 182 | 57 |
| Lisinopril | Lisinopril | 180 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 48 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 162 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 160 | 35 |
| Metformin Hcl | Metformin Hcl | 158 | 54 |
| Aripiprazole | Aripiprazole | 154 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 49 |
| Divalproex Sodium | Divalproex Sodium | 142 | 16 |
| Benztropine Mesylate | Benztropine Mesylate | 141 | suppressed |
| Amoxicillin | Amoxicillin | 138 | 86 |
| Famotidine | Famotidine | 132 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 130 | 19 |
| Azithromycin | Azithromycin | 122 | 81 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 29 |
| Haloperidol | Haloperidol | 117 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 44 |
| Olanzapine | Olanzapine | 109 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 109 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 106 | 70 |
| Tramadol Hcl | Tramadol Hcl | 106 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 38 |
| Pregabalin | Pregabalin | 103 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 99 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 47 |
| Clonidine Hcl | Clonidine Hcl | 89 | 38 |
| Meclizine Hcl | Meclizine Hcl | 85 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 34 |
| Naproxen Sodium | Naproxen Sodium | 79 | 39 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 35 |
| Linzess | Linaclotide | 76 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 11 |
| Haloperidol Decanoate | Haloperidol Decanoate | 74 | suppressed |
| Mounjaro | Tirzepatide | 73 | 21 |
| Eliquis | Apixaban | 70 | 24 |
| Simvastatin | Simvastatin | 68 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 25 |
| Ozempic | Semaglutide | 66 | 21 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 64 | 30 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 63 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 25 |
| Montelukast Sodium | Montelukast Sodium | 63 | 26 |
| Lidocaine | Lidocaine | 62 | 26 |
| Carvedilol | Carvedilol | 59 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 56 | 22 |
| Mirtazapine | Mirtazapine | 54 | suppressed |
| Fluconazole | Fluconazole | 53 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | suppressed |
| Lamotrigine | Lamotrigine | 51 | suppressed |
| Risperidone | Risperidone | 50 | suppressed |
| Cephalexin | Cephalexin | 49 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 42 |
| Glipizide | Glipizide | 47 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 15 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 46 | 25 |
| Nifedipine Er | Nifedipine | 44 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 19 |
| Allopurinol | Allopurinol | 38 | 17 |
| Alendronate Sodium | Alendronate Sodium | 37 | 11 |
| Latanoprost | Latanoprost | 37 | suppressed |
| Methocarbamol | Methocarbamol | 37 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 17 |
| Naproxen | Naproxen | 34 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 33 | suppressed |
| Finasteride | Finasteride | 32 | 11 |
| Metronidazole | Metronidazole | 32 | 23 |
| Lorazepam | Lorazepam | 31 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 16 |
| Donepezil Hcl | Donepezil Hcl | 30 | 15 |
| Farxiga | Dapagliflozin Propanediol | 29 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | 22 |
| Atenolol | Atenolol | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Metolazone | Metolazone | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | 12 |
| Hydrocortisone | Hydrocortisone | 27 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 21 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 20 |
| Ketoconazole | Ketoconazole | 23 | 15 |
| Megestrol Acetate | Megestrol Acetate | 23 | 14 |
| Sucralfate | Sucralfate | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | 18 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Terconazole | Terconazole | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Topiramate | Topiramate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Lamotrigine Er | Lamotrigine | 15 | suppressed |
| Tobramycin | Tobramycin | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lactulose | Lactulose | 13 | 11 |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Abilify Maintena | Aripiprazole | 12 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | 12 |
| Mupirocin | Mupirocin | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,057.47 · 95 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, ARISTADA, Auvelity, BREZTRI, CAPLYTA, COBENFY, CREON, Dexcom G6 Transmitter, FANAPT, FARXIGA, FREESTYLE LIBRE 3, INGREZZA, LEQVIO, LINZESS, LOREEV XR, LYBALVI, MOUNJARO, OTEZLA, QULIPTA, RELISTOR, REPATHA, REXULTI, TRELEGY ELLIPTA, TRULANCE, UBRELVY, Veozah, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error